CNS Drugs

, Volume 15, Issue 1, pp 1–12

The Star Systems

Overview and Use In Determining Antiepileptic Drug Choice
Current Opinion

Abstract

An explosion in antiepileptic drug (AED) therapy began in the 1990s with the licensing of 9 new chemical entities and more to come. Important differences between AEDs may not be detected by regulatory trials, which are designed to satisfy licensing requirements and often diverge considerably from everyday clinical practice. The Star Systems have been developed as evidence-based yet pragmatic and flexible models for comparing AEDs.

Each drug has been judged across a range of criteria, including mechanism of action, pharmacokinetics, ease of use, efficacy, tolerability, safety, interaction profile and a ‘comfort factor’. A score has been allocated under each category and systems have been devised for patients with newly diagnosed epilepsy and those with difficult-to-control seizures requiring combination therapy.

The choice of treatment should involve assessment of patient-related factors, accurate classification of seizure type and syndrome, married with an understanding of the pharmacology of the AEDs. A staged management plan should be formulated when initiating treatment with the aim of preventing the development of refractory epilepsy. When using combinations of AEDs, the mechanism of action of each agent should be taken into consideration.

Such an individualised approach to management will optimise the chance of attaining remission and help many more patients achieve a fulfilling life.

References

  1. 1.
    Brodie MJ, Shorvon SD, Canger R, et al. Commission on European Affairs: appropriate standards of epilepsy care across Europe. Epilepsia 1997; 38: 1245–50PubMedCrossRefGoogle Scholar
  2. 2.
    Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000; 356: 323–9PubMedCrossRefGoogle Scholar
  3. 3.
    Temkin O. The falling sickness: a history of epilepsy from the Greeks to the beginnings of modern neurology. Baltimore: Johns Hopkins, 1971Google Scholar
  4. 4.
    Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168–75PubMedCrossRefGoogle Scholar
  5. 5.
    Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314–9PubMedCrossRefGoogle Scholar
  6. 6.
    Chadwick D. Monotherapy clinical trials of new antiepileptic drugs: design, indications and controversies. Epilepsia 1997; 38 Suppl. 9: 16–20CrossRefGoogle Scholar
  7. 7.
    Brodie MJ. Monostars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia 1999; 40 Suppl. 6: 17–22CrossRefGoogle Scholar
  8. 8.
    Brodie MJ. Lamotrigine versus other antiepileptic drugs: a star rating system is born. Epilepsia 1994; 35 Suppl. 5: 41–6CrossRefGoogle Scholar
  9. 9.
    Brodie MJ, Kwan P. Effectiveness of first ever antiepileptic drug [abstract]. Epilepsia 2000; 41 Suppl. 7: 89Google Scholar
  10. 10.
    Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure 1997; 6: 159–74PubMedCrossRefGoogle Scholar
  11. 11.
    Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalised tonic-clonic seizures. N Engl J Med 1985; 313: 145–51PubMedCrossRefGoogle Scholar
  12. 12.
    Engel Jr J. Surgery for seizure. N Engl J Med 1996; 334: 647–52PubMedCrossRefGoogle Scholar
  13. 13.
    Pellock JM, Brodie MJ. Felbamate: an update. Epilepsia 1997; 38: 1261–4PubMedCrossRefGoogle Scholar
  14. 14.
    Kalvaianen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922–6CrossRefGoogle Scholar
  15. 15.
    White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999; 40 Suppl. 5: 2–10CrossRefGoogle Scholar
  16. 16.
    Brodie MJ, Mumford JP, 012 Study Group. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. Epilepsy Res 1999; 34: 199–205PubMedCrossRefGoogle Scholar
  17. 17.
    Leach JP. Polypharmacy with anticonvulsants: focus on synergy. CNS Drugs 1997; 8: 366–75CrossRefGoogle Scholar
  18. 18.
    Cereghino JJ, Brock JT, Van Meter JC, et al. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975; 18: 733–41PubMedGoogle Scholar
  19. 19.
    Leach JP, Brodie MJ. Synergism with GABAergic drugs in refractory epilepsy. Lancet 1994; 343: 1650PubMedCrossRefGoogle Scholar
  20. 20.
    Stolarek I, Blacklaw J, Forrest G, et al. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 921–4PubMedCrossRefGoogle Scholar
  21. 21.
    Brodie MJ, Yuen AWC, 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res 1997; 26: 423–32PubMedCrossRefGoogle Scholar
  22. 22.
    Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998; 351: 958–9PubMedGoogle Scholar
  23. 23.
    Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000; 9: 464–8PubMedCrossRefGoogle Scholar
  24. 24.
    Brodie MJ. Management strategies for refractory localisation-related seizures. Epilepsia. In pressGoogle Scholar
  25. 25.
    Pisani F, Oteri G, Russo MF, et al. Efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 1141–6PubMedCrossRefGoogle Scholar
  26. 26.
    Brodie MJ. Drug interactions and epilepsy. Epilepsia 1992; 33 Suppl. 1: 13–22CrossRefGoogle Scholar
  27. 27.
    Callaghan N, Kenny RA, O’Neill B, et al. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48: 639–44PubMedCrossRefGoogle Scholar
  28. 28.
    Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765–71PubMedCrossRefGoogle Scholar
  29. 29.
    Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682–7PubMedCrossRefGoogle Scholar
  30. 30.
    Heller AJ, Ring HA, Reynolds EH. Factors relating to dramatic response to clobazam therapy in refractory epilepsy. Epilepsy Res 1988; 2: 276–80PubMedCrossRefGoogle Scholar
  31. 31.
    De Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709–13PubMedCrossRefGoogle Scholar
  32. 32.
    Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476–9PubMedCrossRefGoogle Scholar
  33. 33.
    Bill PA, Vigonius V, Pohlmann H, et al. A double-blind controlled trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195–204PubMedCrossRefGoogle Scholar
  34. 34.
    Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205–13PubMedCrossRefGoogle Scholar
  35. 35.
    Christie W, Kramer G, Vigonius U, et al. A double-blind controlled clinical trial of oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451–60CrossRefGoogle Scholar
  36. 36.
    Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998; 51: 1282–8PubMedCrossRefGoogle Scholar
  37. 37.
    Brodie MJ, Overstall PW, Giorgi L, et al. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999; 37: 81–7PubMedCrossRefGoogle Scholar
  38. 38.
    Brodie MJ, Anhut H, Murray G, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison. Epilepsia 2000; 41 Suppl. Florence: 138–9Google Scholar
  39. 39.
    Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systemic review of their efficacy and tolerability. Epilepsia 1997; 38: 859–80PubMedCrossRefGoogle Scholar
  40. 40.
    Brodie MJ. New antiepileptic drugs: the drugs are not all the same. BMJ 1997; 314: 602–3PubMedCrossRefGoogle Scholar
  41. 41.
    Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, et al. Valproate ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797–802PubMedCrossRefGoogle Scholar
  42. 42.
    Schapel GJ, Black AB, Lam EL, et al. Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure 1996; 5: 51–6PubMedCrossRefGoogle Scholar
  43. 43.
    Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995; 36 Suppl. 3: 46–52CrossRefGoogle Scholar
  44. 44.
    Devinsky O, Vazquez B. Behavioral changes associated with epilepsy. Neurol Clin 1993; 11: 127–49PubMedGoogle Scholar
  45. 45.
    Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383–8PubMedCrossRefGoogle Scholar
  46. 46.
    Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43: 446–51PubMedCrossRefGoogle Scholar
  47. 47.
    Sankar R, Wasterlain CG. Is the devil we know the lesser of two evils? Vigabatrin and visual fields. Neurology 1999; 52: 1537–8PubMedCrossRefGoogle Scholar
  48. 48.
    Yerby MS. Contraception, pregnancy and lactation in women with epilepsy. In: Brodie MJ, Treiman DM, editors. Modern management of epilepsy. London: Balliere’s Clinical Neurology, 1996: 887–908Google Scholar
  49. 49.
    Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy and fetal outcome. Epilepsia 1996; 37 Suppl. 6: S34–44PubMedCrossRefGoogle Scholar
  50. 50.
    Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management of women with epilepsy. Seizure 1999; 8: 201–17PubMedCrossRefGoogle Scholar
  51. 51.
    Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 9: 156–84PubMedCrossRefGoogle Scholar
  52. 52.
    Thomson AH, Brodie MJ. Pharmacokinetic optimisation of anticonvulsant therapy. Clin Pharmacokinet 1992; 23: 216–30PubMedCrossRefGoogle Scholar
  53. 53.
    Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999; 354: 13–9PubMedCrossRefGoogle Scholar
  54. 54.
    Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379–85PubMedCrossRefGoogle Scholar
  55. 55.
    McKee PJW, Brodie MJ. Pharmacokinetic interactions with anticonvulsant drugs. In: Trimble MR, editor. New anticonvulsants: advances in the treatment of epilepsy. London: John Wiley & Sons, 1994: 1–33Google Scholar
  56. 56.
    Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44–50PubMedCrossRefGoogle Scholar
  57. 57.
    Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatry 1984; 27: 1279–82CrossRefGoogle Scholar
  58. 58.
    Hannah JA, Brodie MJ. Epilepsy and learning disabilities: a challenge for the next millenium. Seizure 1998; 7: 3–13PubMedCrossRefGoogle Scholar
  59. 59.
    Brodie MJ. Lamotrigine: an update. Can J Neurol Sci 1996; 23 Suppl. 2: 6–9Google Scholar
  60. 60.
    Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine mono-therapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 601–7PubMedCrossRefGoogle Scholar
  61. 61.
    Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40: 985–91PubMedCrossRefGoogle Scholar
  62. 62.
    Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334: 1583–90PubMedCrossRefGoogle Scholar
  63. 63.
    Gee NS, Brown JP, Dissanaya KE, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha 2 delta subunit of a calcium channel. J Biol Chem 1996; 271: 5768–76PubMedCrossRefGoogle Scholar
  64. 64.
    DeToledo JC, Toledo C, Decorle JD, et al. Changes in body weight with chronic high dose gabapentin therapy. Ther Drug Monit 1997; 19: 394–6PubMedCrossRefGoogle Scholar
  65. 65.
    Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepin in patients with newly diagnosed previously untreated epilepsy. Epilepsy Res 1989; 3: 70–6PubMedCrossRefGoogle Scholar
  66. 66.
    Shorvon S. Oxcarbazepine: a review. Seizure 2000; 9: 75–9PubMedCrossRefGoogle Scholar
  67. 67.
    Fattore C, Cipolla G, Gatti G, et al. Induction of ethinyloestradiol and levonorgestrel metabolism by oxcabazepine in healthy women. Epilepsia 1999; 40: 783–7PubMedCrossRefGoogle Scholar
  68. 68.
    Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic outpatients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224–7PubMedCrossRefGoogle Scholar
  69. 69.
    Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000; 41: 977–80PubMedCrossRefGoogle Scholar
  70. 70.
    Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmackinetics of an oral contraceptive containing norethindrone and ethinyloestradiol in patients with epilepsy. Epilepsia 1997; 38: 317–23PubMedCrossRefGoogle Scholar
  71. 71.
    Leach JP, Brodie MJ. Tiagabine. Lancet 1998; 351: 203–7PubMedCrossRefGoogle Scholar
  72. 72.
    Wilson EA, Brodie MJ. New antiepileptic drugs. In: Brodie MJ, Treiman DM, editors. Modern management of epilepsy. Bailliere’s Clinical Neurology. London: Bailliere Tindall, 1996: 723–47Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Epilepsy UnitUniversity Department of Medicine and TherapeuticsWestern InfirmaryScotland

Personalised recommendations